SK Biopharmaceuticals said Monday it has received US Food and Drug Administration approval to begin a phase 1 clinical trial of its alpha-emitting radiopharmaceutical therapy, marking a key step in its push into next-generation cancer treatments.
The FDA approved the investigational new
Continue Reading on The Korea Herald
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.